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ABSTRACT 
Ganoderma lucidum, Cordyceps militaris, Lignosus rhinocerotis, Pleurotus giganteus, 
Pleurotus floridanus and Auricularia polytricha were screened for fibrinolytic activity 
using fibrin plate assay.  Fibrinolytic activity was identified in the fruiting bodies of the 
medicinal mushrooms L. rhinocerotis and A. polytricha.  However, the present study 
emphasised on the evaluation of the fibrinolytic activity from L. rhinocerotis and its 
partially purified enzyme only.  Fibrin plate assay showed 1.2 cm of lytic zone by the crude 
extracts of L. rhinocerotis which doubled in lytic zone size after overnight incubation, 
which demonstrated the stability of the fibrinolytic enzyme. The extract was initially 
dialysed using 12 kDa cellulose membrane and the solution was freeze-dried and stored 
under -20oC prior to use.  Aqueous two phase system (ATPS), a single-step purification 
method was applied to partition and concentrate the protein. In addition, pre-chilled acetone 
was used to remove contaminants and precipitate the protein through centrifugation at 
13,000 – 15,000 g.  A PEG 8000/ phosphate system comprising of 4.0 g of 50% of 
polyethylene-glycol (PEG), 2.9 g of 40% of phosphate solution and pH 7.0 resulted in the 
concentration of fibrinolytic enzyme in the top phase, with specific activity 151.61 U / mg 
(2.67 fold).  The molecular mass of the partially purified enzyme was identified through 
SDS-PAGE and estimated to be between 55 kDa and 60 kDa.  Native PAGE was carried 
out for gel excision in which band of interested (partially purified enzyme) was excised and 
purified from polyacrylamide gel using elution buffer.  Then, the eluted sample was tested 
on fibrin plate and resulting in the confirmation of the fibrinolytic effect.  
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ABSTRAK 
Ganoderma lucidum, Cordyceps militaris, Lignosus rhinocerotis, Pleurotus giganteus, 
Pleurotus floridanus dan Auricularia polytricha ditapis melalui asai fibrinolitik.  Aktiviti 
fibrinolitik telah dikenalpasti dalam janabuah cendawan perubatan L. rhinocerotis dan A. 
polytricha.  Walau bagaimanapun, kajian ini akan menekankan penilaian aktiviti 
fibrinolitik daripada L. rhinocerotis dan enzim yang separa tulen sahaja. Asai fibrinolitik 
daripada ekstrak mentah L. rhinocerotis menunjukkan zon penguraian sebesar 1.2 cm dan 
membesar dua kali ganda selepas eraman semalaman, di mana ia menunjukkan kestabilan 
enzim fibrinolitik tersebut.  Ekstrak tersebut telah didialisis dengan menggunakan 12 kDa 
membran selulosa sebelum larutan tersebut dikeringkan secara sejuk-beku.  Selepas proses 
pengeringan, ekstrak tersebut disimpan di dalam -20oC sebelum mengguna.  Sistem dua 
fasa cair yang merupakan cara satu langkah penulenan telah digunakan untuk memisah dan 
menumpukan protein.  Secara tambahan, aseton sejuk digunakan untuk mengeluarkan 
bendasing dan memendakkan protein melalui pengemparan pada 13,000–15,000 g.  Sistem 
yang menggunakan PEG 8000/ phosphate mengandungi 4 g daripada 50% polietilena 
glikol (PEG), 2.9 g daripada 40% fosfat larutan dan pH 7.0, telah memberi keputusan di 
mana enzim fibrinolitik telah ditumpukan ke fasa atas dengan aktiviti spesifik 151.61 U / 
mg (2.67 ganda).  Jisim molekul enzim yang ditulenkan telah dianggarkan oleh SDS-PAGE 
dan anggaran jisim molekul adalah 55 kDa dan 60 kDa. Native PAGE telah digunakan 
untuk pemotongan gel di mana enzim yang separa tulen dipotong keluar dan gel 
dibersihkan dengan menggunakan penampan.  Aktiviti fibrinolitik telah dikenalpasti 
daripada enzim-enzim yang dibersihkan.  
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CHAPTER I 
INTRODUCTION 
Mushrooms are commonly used as food, food flavouring substances and traditional 
medicines in eastern countries.  They are reported to be high in protein, with a 
significant content of essential amino acid, but low in fat (Guillamon et al., 2010).  
Besides, mushrooms supply a large amount of carbohydrates, fiber, vitamins (B1, B2, 
B12, C and D) and mineral ions (Ca, K, Mg, Na, P, Cu, Fe, Mn and Se).   
 
The amino acid composition of mushroom proteins is comparable to animal 
protein, and it can counterbalance the high consumption of animal proteins especially in 
developed countries.   Besides, edible mushroom is a unique food which contains many 
different bioactive compounds such as eritadenine (Mattila et al., 1999) and phenolic 
compounds (Barros et al., 2007 & 2008) that may be beneficial in cardiovascular 
disease treatment.  Cardiovascular disease is major cause of death and therefore, there is 
worldwide interest in discovering the potential therapeutic drugs, supplements, and food 
for better health and lifestyle.  
 
In recent years, variety of mushrooms have been studied for their 
pharmacological effect and reported to have great benefits for human health.  These 
mushrooms or their extracts which can be used as therapeutic agents are generally 
known as medicinal mushrooms.  Typically, medicinal mushrooms are edible.  
Nevertheless, edible mushrooms may not necessarily possess therapeutic properties and 
are usually used only as food.   
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According to the world health statistics 2012 by World Health Organization 
(WHO), the annual number of deaths due to cardiovascular disease will increase from 
17 million in 2008 to 25 million in 2030 (World Health Organization, 2012).  In 
Malaysia, the mortality rate from cardiovascular disease in 2008 is 263 deaths per 
100,000 population, and the majority caused by ischaemic heart disease (OECD/WHO, 
2012).  Cardiovascular disease has long been the leading cause of death in developed 
countries.  It becomes increasingly prevalent in Asian countries, comprising about one 
third of all deaths in Asians.  Cardiovascular disease includes a range of diseases that 
are related to circulatory system.  The most prevalent diseases are ischaemic heart 
disease (or heart attack) and cerebrovascular disease (or stroke).  These two diseases 
have contributed to three quarters of all cardiovascular deaths in Asian countries 
(OECD/WHO, 2012).   
 
Atherosclerosis is a condition in which fatty material collects along the walls of 
arteries.  The fatty material thickens and hardens with calcium deposition, and 
eventually blocks the arteries.  Once the blood vessels are injured, platelets tend to 
aggregate and react with fibrin to form thrombus.  Thrombus is abnormal blood clot 
formed within the blood vessel that obstructs the flow of blood and nutrients to vital 
tissue.  When there is phenomenon of reduced blood supply to heart muscle, the 
syndrome is known as Ischaemic heart disease.   
 
In biological system, thrombosis can be prevented through fibrinolysis.  The 
insoluble fibrin fiber is hydrolyzed into fibrin degradation products by plasmin, which 
is generated from plasminogen by plasminogen activators such as the tissue 
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plasminogen activator, vascular plasminogen activator, blood plasminogen activator, 
urokinase, Hageman factor and streptokinase-plasminogen complex (Shen et al., 2007).  
Thrombolytic agents have been extensively used in therapeutic treatment of thrombosis 
nowadays. The commonly used thrombolytic agents include streptokinase, urokinase, 
alteplase, reteplase and tenecteplase.   Thrombolytic drugs breakdown dangerous blood 
clots in blood vessels, improve blood flow, and prevent damage to tissues and organs.  
However, these thrombolytic agents are of relatively high cost and exhibit low 
specificity to fibrin.  Besides, all of these thrombolytic agents could cause undesirable 
side effect such as bleeding complications, which is the most common consequences of 
anticoagulant therapy.  Streptokinase is capable of eliciting antigenic response in human 
since the protein is obtained from streptococci cultures.  The usage of streptokinase is 
previously prohibited or contraindicated because of the risk of anaphylaxis. 
Streptokinase is also relatively non- specific thrombolytic agent which can lead to 
systemic fibrinolysis and lysis of normal hemostatic plugs.    Hence, the search for safe 
thrombolytic agents from other sources is necessary.  Fortunately, fibrinolytic enzymes 
were discovered in insects (Hahn et al., 1999), earthworm (Cho et al., 2004), snake 
venom (Sun et al., 2006) and food-grade microorganism (Wang et al., 2006).   
 
For mushrooms, some studies reported that mushrooms do have therapeutic 
benefit for cardiovascular disease.  The hypocholesterolemic action of edible 
mushrooms has been reported in the early work of Kaneda and Tokuda (1966).  
Lentinus edodes (Berk.) Singer, Auricularia polytricha (Mont.) Sacc., Flammulina 
velutipes (Curtis) Singer and Agaricus bisporus (J.E.Lange) Imbach have been reported 
to have cholesterol lowering properties.  On the other hand, some mushrooms have 
hypotensive effect when blood pressure is already high (Kabir et al., 1987 & 1988; 
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Miyazawa et al., 2008).  Besides, the properties of mushrooms such as antioxidant 
(Cheung et al., 2003; Wong & Chye, 2009) and anti-inflammatory (Jose & Janardhanan, 
2004; Khohno et al., 2008) might be helpful in the management of heart and blood 
circulation.  
 
Today, several mushrooms had been studied for their fibrinolytic activities and 
the corresponding fibrinolytic enzymes were also identified:  Schizophyllum commune 
(Fr) (Lu et al., 2010), Armillariella mellea (Vahl) P. Karst (Kim and Kim, 1999), 
Grifola frondosa (Dicks.) Gray (Nonaka et al., 1997), Pleurotus ostreatus (Jacq.) P. 
Kumm. (Shen et al., 2007) and Fomitella fraxinea (Bull.) Imazeki (Lee et al., 2006).  
Differing from plasminogen activators such as streptokinase and urokinase, these 
fibrinolytic enzymes are plasmin-like proteins which directly perform fibrinolytic action.  
An ideal thrombolytic drug should be effective in breaking down fresh and older 
thrombi, be rapid in its action with complete dissolution of the thrombus, be able to be 
given as a bolus and be safe without hypotensive, allergic or immunogenic reactions 
(Thomson, 1999).   
 
According to current dietary recommendations for health, mushrooms are 
considered as appropriate choice and its consumption can affect some known 
cardiovascular risk biomarkers.  Besides the known hypocholestrolemic effect, the 
presence of antioxidant and anti-inflammatory compound in mushrooms may 
synergistically contribute to reduce the atherosclerosis risk.  Compared to other sources, 
mushrooms are considered as a good choice to treat or prevent cardiovascular disease as 
it can be included in our daily diet and suitable for vegetarians.  Although some 
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mushrooms had been consumed for therapeutic purpose in past, they have yet to 
scientifically verified and reported.  On the other hand, therapeutic effects of 
mushrooms obtained from different geographical region might act differently.  
Therefore, in this study, medicinal mushrooms investigated include Ganoderma 
lucidum (Curtis) P. Karst, Cordyceps militaris (L.) Fr., and Lignosus rhinocerotis 
(Cooke) Ryvarden.  For edible medicinal mushrooms, Pleurotus giganteus (Berk.) 
Karun. & K.D. Hyde, Pleurotus floridanus (Singer) and A. polytricha were studied.   
 
OBJECTIVES: 
The objectives were to: 
a. screen the selected edible and medicinal mushrooms for their fibrinolytic 
activities.  
b. isolate and purify the fibrinolytic enzymes from the mushroom. 
c. characterize the fibrinolytic enzyme by estimation of the molecular mass. 
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CHAPTER II 
LITERATURE REVIEW 
Mushrooms are universally consumed as food, food favouring substances and 
traditional medicines in eastern countries due to its tastiness, high nutritional values, 
and pharmacological properties (Chang & Miles, 1989; Lindequist et al., 2005).  It is 
well established that mushroom extracts contain a wide variety of compounds such as 
protein, polysaccharides, fibre, lectins, and polyphenols, and each of the compounds 
consists its own pharmacological effects (Smiderle et al., 2010).   
 
Lignosus rhinocerotis (Figure 2.1), also known as “tiger milk mushroom”, 
belongs to the Polyporaceae family and is one of the most important medicinal 
mushrooms used by the indigenous people of Southeast Asia and China.  In Malaysia, 
the mushroom is locally named as “cendawan susu rimau” which means tiger’s milk 
mushroom.  It is traditionally used by the natives in peninsular Malaysia as traditional 
medicine to cure cough, fever, asthma, food poisoning and as a general tonic (Lee et al., 
2011).  In China, L. rhinocerus sclerotium is an expensive folk medicine used by 
traditional Chinese physicians to treat liver cancer, chronic hepatitis, and gastric ulcer 
(Wong & Cheung, 2008).  It has more than 15 medicinal uses, however, there are 
limited usage of this mushroom because of its low availability.  The mushroom is 
difficult to cultivate and previously, was only available from forest.  Successful 
cultivation of the mushroom was carried out in agar, solid, and spawn medium with 
good yield, therefore contributing to large quantity production of the mushroom for 
investigation and therapeutic purpose (Lee et al., 2011).  In recent years, variety of 
mushrooms have been tested for their pharmacological effect and reported to have great 
benefits for human health.  The sclerotium of the mushroom is the part of the medicinal 
value and the extracts from it was reported to have in vitro antiproliferative effect on 
leukemic cells and immunodulatory activity (Lai et al., 2008; Wong et al., 2011).  
 
Figure 2.1: Lignosus rhinocerotis. Adapted from Noorlidah et al., 2013. 
 
Mushrooms are reported to be an important source of thrombolytic agents as they 
exert hematological, antiviral, antitumorigenic, hypotensive and hepatoprotective 
effects (Shen et al., 2007).   Many fibrinolytic enzymes were identified in the fruiting 
body of different medical mushrooms such as metalloprotease (AmMEP) from 
Armillaria mellea (Kim & Kim, 1999), aminopeptidase from Grifola frondosa (Nonaka 
et al., 1997), metalloprotease (PoMEP) from Pleurotus ostreatus (Shen et al., 2007) and 
two novel fibrinolytic proteases from Fomitella fraxinea (Lee et al., 2006).  In year 
2010, a novel fibrinolytic protease was discovered from Schizophyllum commune, a 
widely distributed medicinal mushroom, from its mycelium (Lu et al., 2010).  The 
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mushroom was cultured with fermentation technology, and protein purification was 
carried out by cross-flow filtration and fast performance liquid chromatography (FPLC) 
system.  
 
Fibrinolytic activity was determined by the fibrin plate assay in which fibrin clot 
was made in petri dish at room temperature by 1.5% agarose, 0.2% human fibrinogen 
and 10 U of human thrombin, the assay was modified from the method described by 
Astrup and Mullertz, (1952).  For the determination of protease activity, azocasein 
assay was used, where azocasein hydrolysis was used as an measure of fibrinolytic 
activity.  Activity was determined by measuring the release of acid-soluble material 
after protease digestion of azocasein. The protease isolated was fractionated through 
Superdex 75 10/300 GL column and SDS-PAGE.  This enzyme showed 21.32 kDa in 
molecular mass and monomeric form in protein structure.  The effect of temperature 
and pH for optimal protease activity was being estimated as well, the optimal protease 
activity displayed at the condition of pH 5.0 and 45oC.  The activity was enhanced by 
magnesium and inhibited by EDTA.  Despite of low production ratio and recovery rate, 
the fibrinolytic protease revealed 9.29 fold in specific activity after purification, and 
showed greater activity than human plasmin. 
 
2.1  Cardiovascular disease 
Cardiovascular diseases are a group of heart and blood vessels disorders, including 
rheumatic heart disease, hypertensive heart disease, ischemic heart disease, 
cerebrovascular disease, inflammatory heart disease, congenital heart disease and heart 
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failure.   Diseases like acute myocardial, valvular heart disease and stroke is the leading 
cause of death in developed countries (Lu et al., 2010).   
 
2.1.1 Fibrinolysis mechanism  
Fibrinolysis is the aseptic dissolution of fibrin brought about by the direct action of a 
mechanism existing in normal blood (Macfarlane & Biggs, 1948).  Generally, 
dissolutions take days to week to complete, but the action may be accelerated as a result 
of natural changes occurring in the living subject or of experimental procedures as to 
occur within a few hours or minutes (Macfarlane & Biggs, 1948).  This acceleration 
phenomenon had raised the interest of scientists, though a particular set of factors have 
been studied as being apparently those mainly responsible, it is recognized that others 
may be involved.  
 
Under physiological conditions, fibrinolysis is highly regulated mechanism that 
integrates with the coagulation system through several direct molecular links.  Both 
coagulation and fibrinolysis are precisely regulated by measured participation of 
substrates, activators, inhibitors, cofactors and receptors.  Besides preventing blood loss, 
these co-ordinated molecular events insure blood fluidity (Cesarman-Maus & Hajjar, 
2005). Plasminogen (PLG) is a circulating plasma zymogen which can be converted to 
plasmin by both tissue plasminogen activator (tPA) and by urokinase (uPA).  Through 
positive feedback mechanism, plasmin cleaves both tPA and uPA from single chain to 
more active two-chain polypeptides.  Fibrin, which is the substrate to plasmin, bind with 
both plasminogen and tPA on its surface to regulate its own degradation and therefore, 
localizing and enhancing plasmin generation.  Plasminogen activator (tPA) is a weak 
activator in the absence of fibrin, its catalytic efficiency for PLG activation is enhanced 
by at least two orders of magnitude in the presence of fibrin.  In other words, the 
affinity between tPA and plasminogen is low in the absence of fibrin, and vice versa.  
The mechanism of fibrinolytic system is illustrated in Figure 2.2 below.   
 
 
Figure 2.2: Overview of the mechanism of fibrinolytic system. The zymogen 
plasminogen is converted to the active serine protease, plasmin, through the action 
primarily of two-chain tissue plasminogen activator (tc-tPA) or two-chain urokinase (tc-
uPA). These activators are secreted as single-chain (sc-tPA and scuPA) forms from 
endothelial cells, and from renal epithelium, monocyte/macrophages, or endothelial 
cells respectively. Both tPA and uPA can be inhibited by plasminogen activator 
inhibitor-1 (PAI), while plasmin is inhibited by its major inhibitor, a2-plasmin inhibitor 
(a2-PI), and to a lesser extent by a2-macroglobulin (a2-MG). Once plasmin is generated, 
it converts single chain tPA and uPA to double chain forms. It is then rapidly inhibited 
unless it remains bound to fibrin or to its cell surface receptors. Adapted from 
Cesarman-Maus and Hajjar (2005).  
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Plasmin is capable of lysing fibrin, and of digesting fibrinogen, gelatin and casein 
(Macfarlane and Biggs, 1948).  It consists of two fibrinolytic action modes as it 
degrades both fibrin and fibrinogen with different mechanisms.  When plasma 
antiplasmin activity is overhelmed, as when plasminogen activators are used for the 
treatment of thrombosis, circulating fibrinogen may be degraded by plasmin as shown 
in Figure 2.3 (Cesarman-Maus & Hajjar, 2005).   
 
Figure 2.3: Degradation of fibrinogen and cross-linked fibrin by plasmin. Top panel:  
Plasmin initially cleaves the C-terminal regions of the a- and b-chains within the D-
domain of fibrinogen, releasing the Aα- and Bβ-fragments. In addition, a fragment-
containing fibrinopeptide B (FPB) from the N-terminal region of the b-chain is also 
released, giving rise to the intermediate fragment known as ‘fragment X’. Subsequently, 
plasmin cleaves the three polypeptide chains that connect the D- and E-domains, giving 
rise to fragments D, Y and E. Bottom panel: Fibrinogen can also be polymerized by 
thrombin to form fibrin. When degrading cross-linked fibrin, plasmin initially cleaves 
the C-terminal region of the a- and b-chains within the D-domain. Subsequently, some 
of the connecting regions between the D- and E-domains are severed. Fibrin is 
ultimately solubilized upon hydrolysis of additional peptide bonds within the central 
portions of the coiled-coil connectors, giving rise to fibrin degradation products such as 
D-dimer. Adapted from Cesarman-Maus and Hajjar, 2005.  
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Plasmin act on the proteolytic cleavage sites on fibrinogen, and subsequently give 
rise to fragments [Aα, Bβ and fragment fibrinopeptide B (FPB)] for the C- and N- 
termini of fibrinogen’s three polypeptide chains.  The resulting molecule is called 
fragment X which represents a clottable form of fibrinogen.  Additional cleavage results 
in releasing other peptides, and in a series of subsequent reactions, plasmin may further 
cleave the three polypeptide chains that convert the D- and E- domains.  Some of these 
fragments inhibit the spontaneous polymerization of fibrinogen (Cesarman-Maus & 
Hajjar, 2005).  On the other hand, when fibrin cross-linked by factor XIII, is degraded 
by plasmin and subsequently fragments known as D-dimers are released (Cesarman-
Maus & Hajjar, 2005).  In clinical therapy, assays for cross-linked D-dimer fragments 
are employed to identify disseminated intravascular coagulation-like states associated 
with excessive plasmin-mediated fibrinolysis (Cesarman-Maus & Hajjar, 2005).  
 
2.1.2  Atherosclerosis  
Atherosclerosis is a progressive disease characterized by the accumulation of lipids and 
fibrous elements in the large arteries, constitutes the single most important contributor 
to the growing burden of cardiovascular diseases (Libby, 2002).  Several mechanisms 
involved in the antiatherosclerotic effect have been reported (Figure 2.4) (Guillamon et 
al., 2010).  Research in the last two decades has discovered that inflammatory and 
oxidative processes are common features in several cardiovascular conditions, such as 
atherosclerosis (Guillamon et al., 2010).  Abnormal blood clot called thrombus within 
the vascular system is formed by the aggregation of fibrin, and the formation of fibrin is 
triggered from a precursor fibrinogen through the proteolytic action of thrombin.  
Consequently, it obstructs the flow of blood and nutrients to vital tissue. 
In biological system, thromboses can be prohibited through fibrinolysis.  The 
insoluble fibrin fiber is hydrolyzed into fibrin degradation products by plasmin, which 
is generated from plasminogen by plasminogen activators such as the tissue 
plasminogen activator, vascular plasminogen activator, blood plasminogen activator, 
urokinase, Hageman factor and streptokinase-plasminogen complex (Shen et al., 2007).   
 
Figure 2.4: Antiatherosclerotic effects and potential involved mechanisms of different 
edible mushrooms.  Adapted from Guillamon et al., 2010. 
 
 Today, thrombolytic agents have been extensively used in therapeutic treatment 
of thrombosis.  Thrombolytic agents are classified into:  plasminogen activator and 
plasmin-like protein according to their fibrinolysis mechanisms.  Plasminogen 
activators such as tissue-type plasminogen activator (tPA), urokinase-type plasminogen 
activator and bacterial plasminogen activator streptokinase, activate the zymogen 
plasminogen to generate plasmin for fibrinolysis system.  In clinical therapy, 
plasminogen activators are the most widely used among the thrombolytic agents 
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available.  Despite the extensive use, all of these plasminogen activators have 
undesirable side effects such as resistance to reperfusion, the occurrence of acute 
coronary reocclusion, and bleeding complications (Kim & Kim, 1999).  Besides the 
relatively high cost, the thrombolytic agents also exhibit low specificity for fibrin (Shen 
et al., 2007).  Plasmin-like proteins which perform fibrinolytic actions directly were 
discovered from snake venom, earthworm, microorganisms and fermented foods like 
Japanese natto, Korean chungkook-jang and Chinese douchi (Shen et al., 2007).  
 
2.2  Aqueous two phase system (ATPS) 
Aqueous two phase system (ATPS) is an ideal technology combining or integrating 
clarification, concentration, and partial purification into one single step, and therefore it 
is prevalent as it is able to shorten and reduce the purification process of protein.  
Comparing to the conventional liquid-liquid extraction, ATPS has the advantage of 
preserving the targeted biomolecule with high water content of both phases (70-85% 
w/w), high biocompatibility and low interfacial tension, low degradation of 
biomolecules, good resolution, high separation yield, relatively high capacity, ease of 
scale-up, low material costs and the possibility of polymer and salt recycling 
(Ramyadevi et al., 2012).  Hence, ATPS have been studied extensively on a laboratory 
scale for the partitioning of whey milk protein, lysozyme (Su & Chiang, 2006), amino 
acids and peptides (Ramyadevi et al., 2012).  
 
Recently, the potential application of aqueous two phase systems (ATPS) has 
been demonstrated for the recovery of recombinant protein expressed in plants such as 
tobacco and seeds (Gu & Glatz, 2007; Platis & Labrou, 2006).  Ibarra-Herrera et al. 
15 
 
(2011) reported that potential application of selected ATPS as primary step in the 
recovery process of recombinant human proteins expressed in plants green-tissue, 
alfalfa.  The partition using PEG 8000/phosphate systems comprising of 16.1% (w/w) 
of polyethylene glycol (PEG), 10% phosphate, tie-line length of 35.7% (w/w), volume 
ratio equal to one and pH of 7.0 resulted in the potential recovery of 88% of the rhG-
CSF (granulocyte-colony stimulating factor) in the top phase.  Meanwhile, there was 
concentration of 93% of alfalfa contaminant proteins at the interface and bottom phase.   
 
Biopharmaceutical products have been discovered in plant species including 
tobacco, potato, rice, soybean alfalfa, tomato and lettuce (Ma et al., 2003; Stoger et al., 
2002).  Bioproducts were found to have therapeutic value or diagnostics proteins, 
industrial proteins, nutritional supplements such as minerals, vitamins, carbohydrates 
and biopolymers (Ibarra-Herrera et al., 2011).  Several reports have revealed that 
therapeutic proteins produced by the bioreactors obtained from plants consist of several 
advantages.  These advantages include the lack of animal pathogenic contaminants, low 
cost, larger production level, the presence of natural storage organs such as seeds and 
tubers, and existing technology for harvesting and processing of plant material (Ibarra-
Herrera et al., 2011).   
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CHAPTER III 
MATERIALS AND METHODS 
3.1  Preparation of crude extract  
Lyophilised powder of L. rhinocerotis (Tiger milk mushroom), C. militaris, G. lucidum, 
A. polytricha, P. floridanus and P. giganteus were available in the lab and used in this 
study.  For each sample, 10g of the freeze- dried powder was initially suspended in 200 
ml of 20mM Tris-hydrochloride buffer (pH 8.0) [Tris-HCl buffer (pH 8.0)] and then 
physically mixed in an ice bath for 30 minutes. The suspension was then centrifuged at 
10,000 g for 30 minutes at 4 ± 2 oC to remove cell debris.  Then, the supernatant was 
dialysed two to three times using a cellulose membrane with molecular weight 12,000 
kDa cut off range, against distilled water.  The dialysed crude extract was stored at -20 
± 2 oC prior to use.  
 
3.2 Preliminary fibrinolytic assay (fibrin plate method)  
The fibrin plate method used was a modified method from Kim and Kim (1999).  Raw 
fibrin (bovine blood) was freeze-dried and 0.6 % (w/v) freeze-dried fibrin powder was 
dissolved in distilled water followed by homogenation at 11,000 g for 30 seconds.  The 
homogenate was then centrifuged at 2,800 g for 6 minutes to spin down the un-
dissolved fibrin.  The supernatant was collected as fibrin solution and warmed up to 45 
± 2 oC.  Agarose was prepared at 2 % (w/v) with distilled water and maintained at 55 ± 
2 oC.  Fibrin solution was mixed with 2 % agarose in 1:1 ratio and then poured into petri 
dishes.  The clot was allowed to stand for one hour at room temperature.  After the 
medium solidified, a well was made in each of the plates with borer (5mm).  Different 
amount of freeze-dried crude extract was dissolved in 20 mM Tris-HCl buffer to obtain 
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different concentration of the crude extract.  Twenty microliters (20 µl) of crude 
extract/s was dropped into the well and then incubated at 37±2 oC for one hour.  The 
lytic zone (the diameter of clear transparent zone) was measured.  The steps were 
repeated by using 3mg/ml plasmin as positive control and Tris-HCl as negative control.   
 
3.3 Aqueous two phase systems (ATPS)  
The optimised system used was referred from the study of Ibarra-Herrera et al. (2011).  
Four grams of polyethylene glycol 50 % (PEG 50 %) was added with 2.9 g of 
phosphate 40 % and 1 g of sample.  The system was topped up to 10 g by adding 2.1 g 
of distilled water, and then mixed the solution by inverting the tube.  Then, the tube was 
centrifuged at 1,500 g for 10 minutes.  The top and bottom phase was separated into two 
different tubes.  A blank was prepared by replacing the 1 g of sample with 1 g of Tris-
HCl. 
 
3.4 Acetone precipitation of proteins  
Partially purified enzyme from ATPS was precipitated by using acetone precipitation of 
protein method (Wessel & Flugge, 1984).  A required volume of acetone was cooled to 
-20 oC.  Protein sample was placed in acetone-compatible tube.  Four times of the 
sample volume of cold (-20oC) acetone was added.  The tube was mixed using vortex 
and incubated for 60 minutes at -20 oC.  Then, the tube was centrifuged 10 minutes at 
13,000 - 15,000 g.  The supernatant was decanted and disposed properly, being careful 
to not dislodge the protein pellet.  The acetone was allowed to be evaporated from the 
uncapped tube at room temperature for 30 minutes.  Pellet was prevented from being 
over-dried as it may not dissolve properly.  Appropriate amount of distilled water was 
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added for the downstream process and mixed thoroughly through vortex to dissolve 
protein pellet.  
 
3.5 Fibrinolytic activity assay (Folin-spectrophotometry method)  
The crude extract and partially purified enzyme were further evaluated by Folin-
spectrophotometer method (Yun et al., 2003) for their fibrinolytic capacity.  Fibrin was 
dissolved in 0.1 M Mcllvain buffer (pH 7.0) at concentration of 0.6 % (w/v). The 
solution was then homogenised at 11,000 g for 30 seconds followed by centrifugation at 
2,800 g for 10 minutes at room temperature.  Supernatant was collected as fibrin 
solution.  
 
After that, 0.3 ml crude extract or partially purified enzyme was added to 0.6 ml 
fibrin solution and incubated at 40oC for 10 minutes.  The reaction was terminated by 
adding 0.6 ml of 0.55 M trichloro-acetic acid solution for 10 minutes.  Mixture was then 
centrifuged at 2,800 g for 10 minutes to get the supernatant.  One milliliter of 
supernatant was mixed with 1 ml of 0.4 M sodium carbonate and subsequently 0.2 ml (1 
N) of Folin-Ciocalteau reagent.  The mixture was maintained at room temperature for 
30 minutes and absorbance reading was then taken at 660 nm.  A blank was prepared in 
the same way except that 0.3 ml of enzyme sample was replaced with an equivalent 
amount of Mcllvain buffer (pH 7.0) – for crude extract fibrinolytic assay.  Another 
blank was prepared in the same way except that 0.3 ml of enzyme sample was replaced 
with an equivalent amount of ATPS blank – for partially purified enzyme fibrinolytic 
assay.  The fibrinolytic activity was calculated by comparison with a standard curve 
generated using tyrosine.  Crude extract or partially purified enzyme (0.2 ml) was 
mixed thoroughly with 5 ml of Coomassie Brilliant Blue reagent.  Blank was only 0.2 
ml of distilled water with 5 ml of Coomassie Brilliant Blue reagent.  Absorbance was 
taken at 595 nm and the amount of the soluble protein in the sample was calculated by 
using the protein calibration plot.   
 
The protease activity was determined in terms of Units, which was the amount 
in micromoles of tyrosine released from casein per minute.   The calculation for 
protease activity (U/ml) was done by using the formula below: 
Protease activity (U/ml) =  incubation of minutes 10     
extractml3.0
g) ( released tyrosine  L  
While, L-tyrosine released (µg) = 
025.0
y
 
 
The specific activity was determined by dividing the protease activity with the soluble 
protein obtained.   For the calculation of soluble protein (mg/ml), the formula used was, 
Soluble protein (mg/ml) = μg 1000
mg 1
ml 0.2
1
0.007
y   
 
Based on the standard plots, equation for L-tyrosine standard plot was y = 0.025x 
(Figure A.1) whereas equation for bovine serum albumin standard plot was y = 0.007 
(Figure A.2).   
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3.5.1 Preparation of L-tyrosine calibration plot 
The calibration plot (Folin & Marenzi, 1929) was prepared in order to estimate the 
amount of L-tyrosine released at 660 nm on spectrophotometer.  L-tyrosine at 
concentrations from 25 to 200 µM was prepared to generate a calibration plot.  One 
milliliter of different concentrations of L-tyrosine solution was mixed with 1 ml of 0.4 
M sodium carbonate and subsequently 0.2 ml of 1 N Folin-Ciocalteu reagent.  After 30 
minutes, absorbance readings for the mixtures were taken at 660 nm.  A blank was 
prepared in the same way except that L-tyrosine was replaced with 1 ml of 0.1 M 
Mcllvain buffer (pH 7.0).  The absorbance was determined at 660 nm with 
spectrophotometer.   
 
 Preparation of L-tyrosine solution for calibration plot was summarised in the 
Table 3.1.  Conversion of µM of L-tyrosine to µg tyrosine was needed as the unit of 
fibrinolytic activity was defined in µg tyrosine released.  Therefore, the L-tyrosine 
calibration plot was plotted with changes of absorbance against concentrations of L-
tyrosine (µg).  The calculation method for the conversion was described as below: 
 Molecular weight of L-tyrosine = 181.19 g / mol 
 Mole = 
weightmolecular 
x  
 1 mole = 181.19g 
 Mole = 
ml 1000
MV  
 M = mol x 1000 ml / V 
 1 M = 181.19 g  
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 Hence 25, 50, 75, 100, 150 and 200 µM of L-tyrosine were converted to become 
4.53, 9.06, 13.59, 18.12, 27.18 and 36.24 µg respectively.  
 
The changes in absorbance of the crude extracts and partially purified enzyme were 
translated into L-tyrosine released using the L-tyrosine calibration plot with the 
following formula:  
L- tyrosine released (µg) = 
025.0
y  
 
Table 3.1: Summary of experimental procedures for preparation of calibration plot with 
L-tyrosine solution (µM) and the changes of absorbance reading at 660 nm 
Concentration of 
L-tyrosine  
 
(µM) 
L-tyrosine 
stock solution 
  
(ml) 
Weight of 
L-tyrosine  
 
(µg) 
0.1M Mcllvain 
buffer 
 
(ml) 
Absorbance 
reading at 
660nm 
0 0.000 0.000 1.000 0.000 
25 0.050 4.530 0.950 0.116 
50 0.100 9.060 0.900 0.226 
75 0.150 13.590 0.850 0.342 
100 0.200 18.120 0.800 0.460 
150 0.300 27.180 0.700 0.688 
200 0.400 36.240 0.600 0.893 
 
 
3.5.2 Preparation of protein calibration plot  
According to the standard method by Bradford (1976), bovine serum albumin solution 
(BSA) with 10 to 100 µg/ml of protein was prepared and then the final volume was 
made up to 1 ml with distilled water in each test tube.  Blank contained only 1 ml 
distilled water without BSA.  Five milliliters of Coomassie Brilliant Blue reagent was 
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added to each test tube and mixed thoroughly.  After 30 minutes, absorbance readings 
for the mixtures were taken at 595 nm and the weight of protein was plotted against the 
change of absorbance to generate a standard curve. The absorbance readings for 
different concentrations of bovine serum albumin are summarised in the Table 3.2.  
 
Table 3.2:  Standard calibration graph of determination of soluble protein 
Concentration of bovine serum albumin 
(µg/ml) 
Absorbance reading at 595 nm 
0 0.075 
10 0.120 
20 0.218 
30 0.305 
40 0.356 
50 0.472 
60 0.537 
70 0.606 
80 0.688 
90 0.795 
100 0.075 
 
3.6 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
analysis 
Protein samples were analyzed with SDS polyacrylamide gel electrophoresis. Protein 
samples were concentrated and precipitated using pre-chilled acetone solution before 
the SDS-PAGE analysis.  Glass plate and spacer were cleaned and assembled 
“sandwich” in a casting frame.  The lower edges of glass plates and spacers were well 
aligned to make sure there is no leaking of gel.  Then, the whole frame was assembled 
in a casting stand.  Fresh ammoniumpersulfate (APS) solution was prepared in 10% and 
before use only.  Acrylamide gel made up of 12% was used in this study.  Both 
resolving and stacking gel mixture were prepared as shown in Table 3.3.   
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Resolving gel was poured until 2 cm free from the top of the short plate, 
followed by a quick but steady pipette of distilled water onto the top to create a smooth 
top surface.  After 30 minutes, stacking gel solution was prepared when the resolving 
gel had polymerized.  Then, distilled water was poured off from the top of the resolving 
gel completely.  APS and TEMED were then added into the stacking gel solution and 
mixed well by pipetting up and down gently to avoid bubbles.  Then, stacking gel 
solution was poured to the top of the resolving gel and comb was inserted.  The stacking 
gel was left for 30 minutes for it to polymerize.  The gel sandwich was attached to the 
electrode assembly.  When one gel was used, the gasket was turned from the other side 
around and acryl block was put on that side.  Then, running buffer was poured inside 
the gel assembly until the buffer covered and be in contact with the gel.  After make 
sure there is no leakage, buffer was poured into the tank to cover the bottom of the gel.  
Samples were prepared by mixing 15µl of sample and 5µl of sample buffer.  Then, 
electrophoresis was run with 110V for 1 hour 30 minutes.  After electrophoresis, 
polyacrylamide gel was stained with coomassie brilliant blue R-250 for 16-18 hours.   
 
Table 3.3: Preparation of 12% SDS-PAGE gel 
Solutions Resolving gel Stacking gel 
Distilled water 4.4. ml 5.9 ml 
Buffer Tris-HCl (1.5M, pH 8.8) 2.5 ml - 
Buffer Tris-HCl (0.5M, pH 6.8) - 2.5 ml 
10% SDS 0.1 ml 0.1 ml 
40% bis-acrylamide 3.0 ml 1.5 ml 
10% APS 50.0 µl 50.0 µl 
TEMED 10.0 µl 15.0 µl 
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3.7 Protein elution from polyacrylamide gel 
3.7.1 Identification and excision of band of interest  
Instead of SDS-PAGE, the band of interest was obtained from native PAGE.  Native 
PAGE was carried out same method as SDS-PAGE without the presence of SDS.  After 
gel electrophoresis, clean scalpel was used to cut off a strip on the right or left of the gel.  
Then, the strip was placed in a tray for staining while the rest of the gel in a container 
which had filled with distilled water.  The cut strip of gel was stained using coomassie 
brilliant blue R-250 and this strip was used as the ‘reference’ gel strip.  After 30 
minutes, the stained strip of gel was aligned with the unstained gel portion and the band 
of gel that aligns with the stained protein of interest in the reference strip was cut out.  
The entire remaining gel after excision of bands was stained to determine the accuracy 
of excision.   
 
3.7.2 Protein elution from the gel matrix 
Excised gel pieces were placed in clean screw-up culture or microcentrifuge tubes.  
Then, 1ml of elution buffer was added so that the gel pieces were completely immersed.  
Gel pieces were crushed using a clean pestle and incubated in a rotary shaker at 30oC 
overnight.  After that, the tube was centrifuged at 5,000-10,000 g for 10 minutes and the 
supernatant was carefully pipetted into a new microcentrifuge tube.  The eluted sample 
used for fibrin plate assay was prepared from the excised band of interest from native 
page.  A total of 25µl of eluted sample was loaded on each fibrin plate and incubated at 
37oC for one hour.  
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3.8 Statistical Analysis  
Mean values of triplicate data for all the parameters tested were obtained and subjected 
to one-way analysis of variance (ANOVA).  The significant was tested by using the 
multiple range tests at 95% least significant difference (LSD).  The least significant 
difference was conducted to detect any significant difference in fibrinolytic activity of 
L.rhinocerotis enzymes (Appendix B, Table B1 to Table B4).   
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CHAPTER IV 
 
RESULTS 
4.1 Preliminary fibrinolytic assay (fibrin plate method) 
Among the six mushroom samples, both L. rhinocerotis and A. polytricha showed 
fibrinolytic activity (lytic zone observed) in fibrin plates. As the fibrinolytic activity of 
A. polytricha is well documented, this study focused on the potential of L. rhinocerotis 
as a fibrinolytic agent. Several concentrations of the sample were tested in the 
preliminary screening, and the observations are summarized in Table 4.1.   
 
According to Table 4.1, there was no lytic zone observed in the fibrin plate that 
contained 0.2 mg/ml of crude extract.  For the 0.3 mg/ml crude extract, one centimeter 
of lytic zone was observed which indicated the lowest concentration for fibrinolytic 
activity in this study.  The observation showed that crude extracts from 0.4 mg/ml 
increasing to 0.7 did not increase the lytic zone, which was 1.2 cm in diameter.  The 
diameter of lytic zone for positive control was one centimetre, while no lytic zone was 
found in negative control (Tris-HCl buffer).   
 
Table 4.1:  Diameter of lytic zone (cm) observed in 18 plates after one hour of 
incubation at 37±2oC 
Concentration of crude extract (mg/ml) Average of diameter of lytic zone 
(cm) 
0.2 - 
0.3 1.0 ± 0.05 
0.4 1.2 ± 0.05 
0.5 1.2 ± 0.02 
0.6 1.2 ± 0.03 
0.7 1.2 ± 0.02 
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4.2 Fibrin plate assay for crude extract and partially purified enzyme  
The sample was partially purified through aqueous two phase system (ATPS) by using 
the optimized system (Ibarra-Herrera et al., 2010).  In order to determine which phase 
would concentrate the fibrinolytic enzyme, fibrin plate assay was carried out for both 
top and bottom phase of aqueous two phase system.   From the result summarised in 
Table 4.2 and Figure 4.1, the lytic zone observed in crude extract and top phase of 
ATPS was 1.2 cm and 1.0 cm respectively.   
 
For positive control, one centimetre of lytic zone was observed.  While, there 
was no lytic zone for sample bottom phase from ATPS, top and bottom phase of ATPS 
blank, and negative control (Tris-HCl buffer).  The present research found that the 
incubation’s duration of the assay influenced the diameter of lytic zone, the overnight 
plate of crude extract showed a double- increased of diameter (2.6cm) [Figure 4.1(e)].  
 
Table 4.2:  Fibrin plate assay for crude extract and partially purified enzyme 
Sample Diameter of lytic zone (cm) 
Crude extract 1.2 ± 0.01 
Human plasmin (positive control) 1.0 ± 0.01 
Top phase of ATPS 1.0 ± 0.01 
Bottom phase of ATPS - 
Top phase of blank - 
Bottom phase of blank - 
Tri-HCl buffer (Negative control) - 
 
  
(a) (b) (c) 
 
  
(d) (e) 
Figure 4.1: Lytic zone in fibrin plates after the application of samples. (a) 3 mg/ml of 
human plasmin (positive control); (b) Tris-HCl buffer (negative control); (c) ATPS top 
phase; (d) 3 mg/ml of crude extract; (e) 3 mg/ml of crude extract incubated for 16 hours.  
Fibrin plate was prepared from raw fibrin solution and 2% (w/v) agarose solution that 
mixed in 1:1 ratio.  Samples (20 µl) were loaded in the well made by borer and 
incubated at 37 ± 2oC for one hour.  
 
4.3 Fibrinolytic assay (Folin-spectrophotometric method) 
Crude extract and partially purified enzyme were evaluated for their fibrinolytic activity 
by Folin-spectrophotometric method.  Prior to the evaluation of fibrinolytic activity, 
standard curve for L-tyrosine (Appendix A, Figure A.1) and bovine serum albumin was 
plotted (Appendix A, Figure A.2).  Based on the standard plots, equation for L-tyrosine 
standard plot was y = 0.025x (Appendix A, Figure A.1) whereas equation for bovine 
serum albumin standard plot was y=0.007 (Appendix A, Figure A.2).  Specific activity 
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and purification fold of crude extract and partially purified enzyme are summarized in 
Table 4.3.   
 
According to Table 4.3, the protease activity of crude extract was 2.817 U/ml 
which was higher than ATPS top phase and bottom phase, 1.520 U/ml and 0.007 U/ml 
respectively. However, the protease activity of crude extract was lower than the 
protease activity of acetone precipitated ATPS top phase, which was 4.907 U/ml.   
 
Table 4.3: Specific activity and purification fold of crude extract and partially purified 
enzyme from L. rhinocerotis 
Sample Protease activity 
(U/ml) 
Protein 
(mg/ml) 
Specific 
activity 
(U/mg) 
Purification 
fold 
Crude extract  
 
2.817  
(± 0.002) 
0.050  
(± 0.003) 56.850 1.000 
ATPS top phase 
 
 
1.520  
(± 0.240) 
0.015  
(± 0.004) 93.850 1.650 
ATPS bottom 
phase 
 
 
0.007  
(± 0.010) 
0.005 
(± 0.007) 1.390 0.020 
Acetone 
precipitated 
protein  
(ATPS top phase) 
4.907  
(± 0.350) 
0.032 
(± 0.004) 151.610 2.670 
 
The concentration of protein was measured using Bradford protein assay.  Crude 
extract contained the highest amount of protein, 0.05 mg/ml, whereas ATPS bottom 
phase contained the lowest amount of protein, 0.005 mg/ml.  ATPS top phase contained 
0.015 mg/ml of protein which was higher than ATPS bottom phase but lower than crude 
extract and acetone precipitated ATPS top phase (0.0324 mg/ml).  
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For specific activity, acetone precipitated ATPS top phase showed the highest 
activity which was 151.61 U/mg, followed by 93.85 U/mg from ATPS top phase, 56.85 
U/mg from crude extract and the lowest specific activity was 1.39 U/mg from ATPS 
bottom phase.  The partially purification method resulted in a 2.67 fold purification of 
the enzyme.   
 
Based on Table B.1 in Appendix B, the sample was said to be normally 
distributed since all the p-values were greater than the significant level of 0.05 in the 
normality test.  Levene Test was not significant as the p-value was greater than 0.05, we 
could assume that the data showed homogeneity of variances (Appendix B, Table B.2).   
For ANOVA test, the p-value was less than 0.05, which showed that there were 
significant differences between the groups (Appendix B, Table B.3).   Using Duncan 
post-hoc test, the degree of specific activity was determined where acetone precipitated 
protein showed the highest activity while ATPS bottom as the lowest (Appendix B, 
Table B.4). 
 
4.4  Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
analysis 
The molecular mass of the partially purified enzyme was estimated by SDS-PAGE.  
SDS-PAGE analysis of crude extract and partially purified enzyme and were shown in 
Figure 4.2(a) and Figure 4.2(b) respectively.  The SDS-PAGE image shown in Figure 
4.2(a) illustrates the proteins present in crude extract of L. rhinocerotis.  Based on the 
SDS-PAGE image shown in Figure 4.2(b), the partially purified enzyme showed double 
bands on SDS-PAGE, with the molecular weight of 55 kDa and 60 kDa approximately.  
 ~60k 
~55k 
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 Figure 4.2(a): Molecular mass 
determination of crude extract on 
SDS-PAGE. Lane: M = Protein 
molecular weight standards; 
1=Crude extract.  
Figure 4.2(b): Molecular mass 
determination of partially purified 
enzyme on SDS-PAGE. Lane: M = 
Protein molecular weight standards; 
1= Partially purified enzyme. 
 
 
4.5 Elution of protein from band of interest  
The partially purified enzyme was the fibrinolytic enzyme that present in L. 
rhinocerotis. In order to reconfirm the presence of the fibrinolytic effect, biological test 
was carried out.  In this study, fibrin plate assay was used as the biological test.  The 
band strips of interest obtained from native page gel were crushed gently and eluted by 
using buffer (50 mM Tris-HCl, 150 mM NaCl; pH7.5).  The supernatant of the eluted 
protein were tested on fibrin plates, and as a result, the eluted protein showed visible 
digestive zone, with measurement of diameter 1.3 cm and 1.2 cm respectively [Figure 
4.3 (a) and (b)]. 
  
(a) (b) 
 
(c) (d) 
Figure 4.3:  Fibrin plate assay of eluted protein.  (a) eluted protein of ~60kDa band; (b) 
eluted protein of ~55kDa band; (c) elution buffer (negative control).  
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CHAPTER V 
DISCUSSION AND CONCLUSIONS 
5.1 Preparation of crude extracts 
The supernatant of crude extract was dialyzed in order to remove protein of smaller 
molecular weight.  Cellulose membrane with 12 kDa cut off range was used in the 
dialysis process since the molecular mass of fibrinolytic enzyme obtained from a related 
source, honey mushroom (A. mellea) fruiting bodies was 18 kDa (Kim and Kim, 1999).  
Besides, fibrinolytic protease purified from S. commune, one of the medical mushrooms 
was reported to have 21.32 kDa (Lu et al., 2010).  In addition, the molecular mass of 
fibrinolytic metalloprotease discovered from P. ostreatus was estimated to be 32 kDa 
(Shen et al., 2007).   
 
According to Dixon et al. (1979a), drying in high vacuum at low temperature 
from the frozen state was useful in producing an active and soluble powder which can 
be stored at room temperature.  Hence, freeze-dried sample was preferred in this study 
since fibrinolytic enzyme can be preserved better during the freeze-drying process. 
Besides, the crude extract of freeze-dried fruit bodies showed the highest fibrinolytic 
activity using the fibrin plate assay compared to the fresh and oven-dried fruit bodies 
obtained in a previous study by Kho (2008).  Hence, the dialyzed crude extract used in 
this study was freeze-dried.    
 
One of the factors that affect the protein stability during the preparation of crude 
extracts was temperature, especially high temperature.  Due to thermal stability, many 
34 
 
proteins could be slowly denatured above 25oC.  Hence, the preparation of crude 
extracts in this study was performed on an ice bath (4oC).   
 
Besides temperature, constant pH of buffer was essential to maintain protein 
stability (Hames and Hooper, 2000).  In this study, Tris-HCl buffer with constant pH of 
8.0 was used.  Tris buffer was preferred since it is comparatively inexpensive, very 
freely soluble in water, inert in the enzymatic system and had a high buffer capacity.  In 
addition, the sample powder was physically mixed instead of blending and 
homogenizing so as to minimize frothing and at the same time, maintaining the stability 
of the protein.   
 
Many proteins could be denatured by contact with the air-water interface, and 
significant fraction of protein may be lost through adsorption to surfaces.  Therefore, 
the sample powder and solvent buffer were mixed in 1:20 ratio to make sure that 
enzyme was relatively concentrated and fully dissolved (Mohammad Ali et al., 2014).   
 
 
5.2  Preliminary fibrinolytic assay (fibrin plate method) 
In this study, increased concentration of the L. rhinocerotis sample resulted in the 
increment of the size of the lytic zone, which indicating increase of the fibrinolytic 
activity.  At the concentration of 0.4 mg/ml to 0.7, the lytic zones observed were 
constant which was 1.2 cm in diameter.  In fact, the slight increase of the fibrinolytic 
activity could not be accurately determined through the fibrin plate assay.  Hence, 
quantitative assay was carried out in this study.  Fibrinolytic effect of traditional 
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medicinal mushrooms, G. lucidum and C. militaris, has been previously reported 
(Kumaran et al., 2011 and Cui et al., 2008). However, there was no fibrinolytic activity 
observed with this mushroom and this might be due to the geographical factors that 
could affect the properties of the mushrooms.     
 
The fibrin plate assay used in this study was modified from the method of Kim 
and Kim (1999) in which raw bovine blood collected from local abattoir was utilized as 
raw blood fibrin.  In place of the purified protein that available in market, raw bovine 
blood was preferred to be used due to several reasons.  Besides low material cost, raw 
bovine blood could form blood clot naturally which was considered as a more suitable 
model for fibrin clot formation in this study.   The utilization of whole bovine blood 
may reduce the loss of any co-factor and co-enzyme which involved in the fibrin clot 
formation (Kho, 2008).   
 
In the fibrin plate assay, clear transparent regions indicated hydrolysis of fibrin, 
and its lytic zone diameter was directly proportional to the potency of the fibrinolytic 
activity.  A borer was used to make well in fibrin plate so that sample was loaded in the 
center of fibrin plate without spreading, as an even circular shape of lytic zone was 
necessary for diameter estimation.  The incubation temperature was set at 37oC to give 
optimal enzymatic activity.  
 
During the preparation of fibrin plates, the fibrin agarose mixture must be 
poured evenly in every plate in terms of the thickness of the fibrin agar.  The ideal 
thickness of the fibrin agar was the thickness in which the level was parallel to the 
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height of 20µl of sample loaded in the well.  This is to ensure the accuracy and 
reproducibility of the estimation of fibrinolytic activity.   
 
5.3 Purification of fibrinolytic enzyme 
Crude extracts are complex mixture which contains substances that will interfere with 
the downstream applications.  Hence, purification is necessary to extract certain specific 
enzyme from the complex mixture.  The conventional methods of purification of 
biomolecules involve several steps of operations and therefore are usually expensive.  
Moreover, some quantity of target molecule is lost in each step of purification and 
resulting in a big overall loss.  The aqueous two phase system (ATPS) is an alternative 
method for the separation of biomolecules which reduces number of steps and also the 
cost of operation.  The technique is used in recovery and purification of many biological 
products including proteins, genetic material, bionanoparticles, cells and organelles 
(Andrews and Asenjo, 2010; Rito-Palomares, 2004).  
 
 Complete phase separation was achieved when two phases were formed.  The top 
phase was polymer phase and the bottom phase was the salt phase.  The fibrinolytic 
enzyme should be concentrated in one of the phases and the contaminants in the other.  
The phase preferences were attributed to the hydrophilic nature of the proteins present 
in the extracts and the effect of system parameters on the partition behaviour of the 
proteins (Ibarra-Herrera et al., 2011).  Parameters were manipulated to partition the 
enzyme in polymer (PEG with molecular weight of 8000 g mol-1) because the presence 
of salt may interfere the downstream applications.  Based on Ibarra-Herrera et al. 
(2011), ATPS using PEG with molecular weight of 8000 g mol-1 can be easily 
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implemented for the recovery of hydrophobic proteins that exhibit top phase preference. 
The fibrinolytic protease from Streptomyces sp. DPUA1576 was partitioned 
preferentially to the PEG rich phase under these conditions (Medeiros e Silva et al., 
2013).  In addition, protease extraction through ATPS was reported from A. bisporus, in 
which the protease was also partitioned to the PEG rich phase (Deloisa et al., 2009).   
   
 Due to cost considerations, the aqueous two phase polymer/salt system was 
preferred over the other systems.  Polymer/salt systems have advantages including 
larger differences in density, greater selectivity, lower viscosity, lower cost and larger 
relative size of the drops (Chunha and Aznar, 2009). Polyethylene glycol (PEG) was 
used as the polymer in ATPS because it is available at low cost and able to form a two-
phase system with salts.  In addition, PEG can significantly enhance the refolding of 
proteins to recover the activity (Cleland et al., 1992).  
 
There are several factors that influence the recovery of biomolecules from a 
mixture by ATPS such as phase components and their concentration, tie-line length 
(TLL), pH, temperature, and sample concentration.  In order to optimize the ATPS, 
many number of experiments have to be carried out.  This is laborious, time consuming 
and increases the overall cost.  Different systems selected for ATPS could allow 
differential partitioning between target protein and contaminants.     Therefore, the 
system selected for the evaluation of the partition behaviour of the proteins from L. 
rhinocerotis was based on the previous experiences by Aguilar and Rito-Palomares 
(2008).  The strategy behind the selection of the experimental systems was well 
explained in another paper of Rito-Palomares (2004).  According to Aguilar et al. 
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(2006), the system tie-line length (TLL) that represents the length of the line which 
connects the compositions of the top and bottom phases in a phase diagram for a 
defined system, was calculated and described.  In addition, the application of the 
selected system on other mushroom samples was investigated in the laboratory recently 
and showed ideal results.   
 
Using ATPS, it is necessary to precipitate and concentrate the proteins after the 
partitioning step.  In this study, acetone precipitation of proteins was employed to 
remove undesirable substances which may interfere with downstream applications and 
analyses.  After centrifugation to pellet the precipitated proteins, the supernatant which 
contained the interfering substances was discarded.  The acetone precipitation of protein 
step was performed once only instead of repeating the purification step to prevent 
sample loss in each cycle of precipitation.   
 
5.4  Fibrin plate assay for crude extract and partially purified enzyme  
Fibrinolytic activity was observed in both the crude extract and partially purified 
enzyme of L. rhinocerotis when assayed by using fibrin plate after one hour of 
incubation.  In comparison, fibrinolytic activity of the culture filtrate from C. militaris 
was observed after 5 hours when it was incubated in fibrin plate (Cui et al., 2008).  
Therefore, the result explains that the fibrinolytic enzyme found in L. rhinocerotis is 
higher than in C. militaris a property might be helpful in the thrombolytic therapy in the 
future.  On the other hand, the present study found that the fibrinolytic activity of L. 
rhinocerotis was stable overnight.  A 2x increase of the lytic zone was observed after 16 
hours which demonstrate the stability of the enzyme derived from L. rhinocerotis.  The 
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partially purified enzyme obtained in the top phase of ATPS had a slightly smaller 
diameter lytic zone on the fibrin plate than the crude extract of freeze dried L. 
rhinocerotis.  The result may due to the amount of the fibrinolytic enzyme recovered 
was reduced throughout each of the purification process.  
  
5.5 Fibrinolytic assay (Folin-spectrophotometric method) for crude extracts and 
partially purified enzyme preparations 
The fibrinolytic protease from L. rhinocerotis in top phase of ATPS showed the highest 
specific activity after partitioning and precipitation by cold acetone (151.61 U/mg).  It is 
because protein was concentrated through the precipitation action on the partially 
purified enzyme produced by ATPS, while a number of contaminants in the sample had 
been eliminated after partitioning by ATPS.  This assay showed that the purification 
fold in the top phase of ATPS (1.65 fold) was higher than in the bottom phase (0.02 
fold).  It was demonstrated that fibrinolytic enzyme was well partitioned into top phase.  
The top phase of ATPS is usually the polymer (PEG) which was hydrophobicity, and 
hence, the hydrophobic protein preferably partitioned in the top phase of ATPS 
(polymer phase).  There was a small detection of activity in the bottom phase of ATPS 
and some of them had no activity at all.  It may be caused by technical error during 
pipetting out the bottom phase solution.  The bottom phase solution might have mixed 
with some amount of the ATPS top phase solution causing a small detection of 
fibrinolytic activity.  As compared to the recent study by Mohamed Ali et al. (2014), the 
fibrinolytic enzyme from a mushroom was also partitioned to the top phase of the ATPS 
and with good recovery outcome.  
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From the result shown in Table 4.3, the specific activity of ATPS top phase 
protein after acetone precipitation was 2.67 fold.   In the report by Kim and Kim (1999), 
the specific activity of the fibrinolytic enzyme from the sample A. mellea was 2.41 fold 
after ammonium sulphate precipitation.  As a comparison, the purification fold found in 
this study is slightly higher than the ammonium sulphate purification method.  Hence, 
ATPS may be considered as a better option since the recovery of the fibrinolytic 
enzyme in mushroom using ammonium sulphate extraction method was low (Mohamed 
Ali et al., 2014).  The utilization of ATPS for primary recovery of phytase produced by 
S. commune was reported in a recent study by Salmon et al., (2014) with considerably 
high purification fold (5.43) of protein, which indicated the efficiency of the method.  
   
 The Enzyme Commission recommended that specific activity should be given as 
unit per mg protein.  Therefore, Folin-Ciocalteau reagent was used in the present study 
to estimate the quantity of fibrinolytic enzyme more accurately.  This reagent reacted on 
chromogenic nature of the amino acid (tyrosine) side chain was sensitive, enabling it to 
detect 0.01 to 0.1 mg of protein in the assay (Dixon and Webb, 1979b).   
 
 Folin-spectrophotometric method was used in the assay of fibrinolytic activity 
because of its simplicity, sensitivity and ease.  According to Dixon and Webb (1979b), 
enzyme unit is defined in term of the change of absorbance in a certain time of 
incubation with other reaction conditions being constructed.  Ten minutes of incubation 
time at 40oC was used in this study. These conditions were sufficient to assay as a 
fibrinolytic activity because of short reaction time.           
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 In this assay, casein was the substrate and when protease broke peptide bonds of 
casein, the amino acid tyrosine was released along with other amino acids and peptide 
fragments.  Folin’s reagent reacted primarily with free tyrosine to produce a blue 
colored chromophore, which was quantifiable and measurable as an absorbance value at 
660 nm in a UV spectrophotometer.  The absorbance values generated by the activity of 
protease were compared to a standard curve.  The amount of tyrosine released was 
proportional to the protease activity.  In other words, the more the chromophore were 
generated, the greater the protease activity.   
 
5.6 Molecular mass estimation for partially purified enzyme 
The molecular weights of the partially purified enzyme were confirmed as 55kDa and 
60kDa after the fibrin plate assay and gel elution. The highest molecular weight of 
fibrinolytic enzyme was reported in G. lucidum (100kDa), whereas the lowest in 
Pleurotus eryngii (14kDa) (Choi and Sa, 2000; Lu and Chen, 2012).  The molecular 
weights found in this study were closest to the molecular weight reported in A. 
polytricha, which is 66kDa (Mohamed Ali et al., 2014).  The molecular weight of the 
fibrinolytic enzyme found in this study did not match to the reported ones.  In fact, the 
molecular weight of the fibrinolytic protease might differ from diverse species (Choi et 
al., 2011).   
 
The purpose of the SDS (sodium dodecyl sulfate) detergent was to denature the 
proteins and dissociate them from each other.  Besides, it solubilizes all proteins and 
then covered the proteins with negative charges.  During SDS-PAGE, all proteins 
migrate downwards to the positively charged electrode (anode).   Good quality of SDS 
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was used to ensure that sharp protein bands were observed.  Poor quality or old SDS 
would cause protein with stained background along the individual gel tract with 
indistinct protein band.  The concentration of SDS should not be too high as high 
concentration of SDS might interfere with Coomassie Blue staining.       
 
5.7 Native PAGE and excision of band of interest 
Both of the bands on native PAGE were eluted in order to detect the enzyme activity.  
The partially purified enzyme from L. rhinocerotis exhibited fibrinolytic activity. In 
order to reconfirm the presence of the fibrinolytic effect, its biological activity was 
assayed.  In this study, fibrin plate assay was used as the biological assay.  The bands of 
interest (55kDa and 60kDa) were excised from native page gel, crushed gently and the 
protein eluted by using buffer (50 mM Tris-HCl, 150 mM NaCl; pH7.5).  Native PAGE 
was employed instead of SDS-PAGE for gel excision because active and non-
denaturing conditions were necessary for biological assay.  In the present study, the 
eluted protein showed fibrin digestion and confirmed the fibrinolytic activity of L. 
rhinocerotis.  
 
5.8 Recommendations for future studies 
Future study may focus on the large scale of the protein purification through aqueous 
two phase system (ATPS) in the considerations of commercial use of the product.  In 
addition, blood parameters such as C-reactive protein, fibrinogen, leukocyte count, 
monocyte count, total cholesterol, high density lipoprotein-cholesterol, LDL-cholesterol 
and triglycerides in animal models should be evaluated in order to characterize the in 
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vivo potential of this enzyme to reduce the risk of the cardiovascular disease (Boudjeltia 
et al., 2006).   
 
5.9  Conclusions  
Lignosus rhinocerotis and A. polytricha were found to exhibit fibrinolytic activities, 
while P. giganteus and P. floridanus did not show any fibrinolytic activity.  However, G. 
lucidum and C. militaris which were recognized traditional medicinal mushrooms were 
found to have no fibrinolytic activity.   
  
This was the first report of fibrinolytic activity of L. rhinocerotis.  The fibrin 
plate assay result had shown that L. rhinocerotis had the potential to lyse the fibrin clot.  
Besides, the fibrinolytic effect remained after overnight (16 hours), which demonstrated 
the stability of the fibrinolytic activity. The specific activity of the crude extract 
evaluated through Folin-spectrophotometric method was 56.85 U/mg.   
  
The fibrinolytic enzyme in crude extract from L. rhinocerotis was partially 
purified through aqueous two phase system (ATPS) and subsequently concentrated by 
using cold acetone.  Fibrin plate assay was employed to examine fibrinolytic activity of 
the ATPS partitions (top and bottom phases).  The assay demonstrated that the 
fibrinolytic enzyme showed more affinity to top phase compared to the bottom phase.  
After evaluation by using the Folin-spectrophotometric method, the specific activity of 
the partially purified enzyme was 151.61 U / mg, which represented a 2.67 of 
purification fold.   
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 The molecular mass of the partially purified enzyme estimated through SDS-
PAGE and resulted was 55 kDa and 60 kDa approximately.  Native PAGE and gel 
purification step was carried out and confirmed the fibrinolytic activity of the partially 
purified enzyme. 
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Appendix A: MEDIA AND METHODS 
A.1 Reagents 
20mM Tris-HCl buffer (pH 8.0), 0.1 M citric acid, 0.2 M disodium hydrogen phosphate, 
0.1 M Mcllvain buffer (pH 7.0), 0.55 M trichloro-acetic acid solution, 0.4 M sodium 
carbonate, 1 N Folin-Ciocalteus reagent, and L-tyrosine, 95% ethanol, Coomassie 
Brilliant Blue solution and bovine serum albumin stock solution. 40% phosphate stock 
solution and 50% PEG stock solution 
 
A.2 Preparation of reagents 
A.2.1 20 mM Tris-HCl buffer (pH 8.0) 
 Molecular weight of trizma = 121.14 g/mol 
 To prepare 1000 ml, 
Mole = 
ml 1000
ml)1000( M1020 3
 
         = 0.02 mol 
 0.02 mole = 
mol / g 14.121
x
 
 x = 2.4228 g 
 To prepare 20 mM Tris-HCl buffer (pH 8.0), 2.4228 g of trizma was dissolved 
in 900 ml of distilled water and pH was adjusted to pH 8.0 with HCl before the 
final volume was brought to 1000 ml with distilled water 
 
A.2.2 0.1 M citric acid solution  
 Molecular weight of citric acid = 210.14 g / mol 
 To prepare 100 ml, 
Mole = 
ml 1000
ml 100  M 1.0 
 
         = 0.01 mol 
 0.01 mole = 
mol / g 210.14
x
 
 x = 2.1014 g 
 To prepare 0.1 M citric acid solution, 2.1014 g of citric acid was dissolved in 
100 ml of distilled water.  
 
A.2.3 0.2 M disodium hydrogen phosphate solution 
 Molecular weight of disodium hydrogen phosphate = 141.96 g / mol 
 To prepare 1000 ml, 
Mole = 
ml 1000
ml 1000  M 0.2 
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         = 0.2 mol 
 0.2 mole = 
mol / g 141.96
x
 
 X = 28.392 g 
 To prepare 0.2 M disodium hydrogen phosphate solution, 28.392 g of disodium 
hydrogen phosphate was dissolved in 1000 ml of distilled water. 
 
A.2.4 0.1 M Mcllvain buffer (pH7.0) 
 To prepare 100 ml of 0.1 M of Mcllvain buffer (pH7.0), 17.65 ml of 0.1 M citric 
acid was mixed thoroughly with 82.35 ml of 0.2 M disodium hydrogen 
phosphate solution. 
 
A.2.5 0.55 M trichloro-acetic acid solution 
 Molecular weight of trichloro-acetic acid = 163.39 g / mol  
 To prepare 100 ml, 
Mole = 
ml 1000
ml 100  M 55.0 
 
         = 0.055 mol 
 0.055 mole = 
 /molg 163.39
x
 
 X = 8.9865 g 
 To prepare 0.55 M trichloro-acetic acid solution, 8.9865 g of trichloro-acetic 
acid was dissolved in 100 ml of distilled water.  
 
A.2.6 0.4 M sodium carbonate 
 Molecular weight of sodium carbonate = 105.99 g / mol 
 To prepare 100 ml, 
Mole = 
ml 1000
ml 100  M 4.0 
 
=0.04 mol 
 0.04 mole = 
mol / g 105.99
x
 
 x = 4.2396 g 
 To prepare 0.4 M sodium carbonate, 4.2396 g of sodium carbonate was 
dissolved in 100ml of distilled water. 
 
A.2.7 1 N Folin-Ciocalteu reagent 
 To prepare 1 N Folin-Ciocalteu reagent, Folin-Ciocalteu reagent stock (2 N) was 
mixed evenly with distilled water in 1:1 ratio and kept in dark prior to use.  
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A.2.8 L-tyrosine stock solution 
 Molecular weight of L-tyrosine = 181.2 g / mol 
 To prepare 1000 ml, 
Mole = 
ml1000
ml) (1000 M 10  500 -6
 
         = 0.0005 mol  
 0.0005 mole = 
mol / g 181.2
x
 
 X = 0.0906 g 
 To prepare 500 µM L-tyrosine, 0.0906 g of L-tyrosine was dissolved in 1000 ml 
of 0.1 M Mcllvain buffer (pH 7.0) 
 
 
A.2.9  95% ethanol 
 95 ml of pure ethanol (100%) was mixed thoroughly with five milliliters of 
distilled water. 
 
A.2.10 Coomassie Brilliant Blue solution 
 To prepare 1 L of Coomassie Brilliant Blue solution, approximately 100 mg of 
Coomassie Brilliant Blue G-250 was dissolved in 50 ml of 95% ethanol.  After 
that, 100ml of 85 % (w / v) phosphoric acid was added into this mixture and 
brought up to final volume of 1 L. 
 
A.2.11 Bovine serum albumin stock solution 
 0.01 % (w / v) of bovine serum albumin stock solution was prepared by 
dissolving 0.01 g of bovine serum albumin in 100 ml of distilled water. 
 
A.2.12 40% phosphate stock solution 
 To prepare 100g, 
21.7g of K2HPO4 mixed with 18.3 g of KH2PO4 and 60 g of distilled water. 
 
A.2.13 50% PEG stock solution 
 To prepare 80 g, 
40 g of PEG 8000 was mixed with 40 g of distilled water.  
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A.3 L-tyrosine calibration plot (Folin & Marenzi, 1929) 
 
Figure A.1:  L-tyrosine calibration plot for fibrinolytic activity 
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A.4  Protein calibration plot (Bradford, 1976) 
 
Figure A.2: Protein calibration plot for determination of soluble protein 
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Appendix B: STATISTICAL ANALYSIS 
B.1 Normality test and Homogeneity of Variances 
Table B.1: Normality test - Fibrinolytic activities of crude extract and partially 
purified enzymes from L. rhinocerotis  
 Kolmogorov-Smirnova Shapiro-Wilk 
 
Samples 
Statistic df Sig. Statistic df Sig.
Crude extract .369 3 . .789 3 .088
ATPS Top .312 3 . .896 3 .374
ATPS Bottom .185 3 . .998 3 .923Specific_activity 
Acetone precipitated 
protein .233 3 . .979 3 .722
a. Lilliefors Significance Correction 
 
 
B.1.1 Test of homogeneity of variances 
Table B.2: Test of homogeneity of variances - Fibrinolytic activities of crude extract 
and partially purified enzymes from L. rhinocerotis 
Levene Statistic d.f. 1 d.f. 2 Sig. 
3.312 3 8 .078
 
 
B.2 One-way ANOVA  
Table B.3: ANOVA - Fibrinolytic activities of crude extract and partially purified 
enzymes from L. rhinocerotis 
 Sum of 
Squares 
d.f. Mean of 
square 
F-ratio Sig. level 
# 
Between Groups 35906.922 3 11968.974 1348.695 .000
Within Groups 70.996 8 8.874   
Total 35977.917 11    
# p = 0.0000 (denotes a statistically significant difference) 
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B.3  Post-Hoc for ANOVA 
Table B.4: Duncan post-hoc test - Fibrinolytic activities of crude extract and partially 
purified enzymes from L. rhinocerotis 
 Subset for alpha = 0.05 
 
Samples N 
1 2 3 4 
ATPS Bottom 3 1.3900    
Crude extract 3  56.8467   
ATPS Top 3   93.8500  
Acetone precipitated 
protein 3
   151.6100
Duncana 
Sig.  1.000 1.000 1.000 1.000
Means for groups in homogeneous subsets were displayed. 
a. Uses Harmonic Mean Sample Size = 3.000. 
 
 
 
Appendix C:  RAW DATA 
 
Table C.1:  Diameter of lytic zone (cm) observed in 18 plates after one hour of incubation at 37±2oC 
Concentration of crude extract (mg/ml) Replicate Diameter of lytic zone (cm) 
0.2 1 - 
 2 - 
 3 - 
0.3 1 1.00 
 2 1.00 
 3 1.09 
0.4 1 1.20 
 2 1.10 
 3 1.20 
0.5 1 1.23 
 2 1.21 
 3 1.19 
0.6 1 1.23 
 2 1.21 
 3 1.18 
0.7 1 1.19 
 2 1.21 
 3 1.23 
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Table C.2:  Fibrin plate assay for crude extract and partially purified enzyme 
Sample Replicate Diameter of lytic zone (cm) 
Crude extract 1 1.21 
 2 1.23 
 3 1.22 
Human plasmin (positive control) 1 1.40 
 2 1.20 
 3 1.30 
Top phase of ATPS 1 1.04 
 2 1.02 
 3 1.03 
Bottom phase of ATPS 1 - 
 2  
 3  
Top phase of blank 1 - 
 2  
 3  
Bottom phase of blank 1 - 
 2  
 3  
Tri-HCl buffer (Negative control) 1 - 
 2  
 3  
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Table C.3: Fibrinolytic activities of crude extract and partially purified enzymes from L. rhinocerotis 
Sample Replicate Protease activity (U/ml)  Protein (mg/ml) Specific activity (U/mg) purification fold 
1 2.790 0.047 59.360 
2 2.840 0.051 55.686 
Crude extract 
3 2.830 0.051 55.490 
1.000 
1 1.510 0.016 92.073 
2 1.060 0.011 92.982 
ATPS top phase 
3 1.930 0.020 96.500 
1.650 
1 0.007 0.005 1.400 
2 0.007 0.006 1.167 
ATPS bottom phase 
3 0.008 0.005 1.600 
0.020 
1 5.000 0.034 147.059 
2 4.820 0.031 157.003 
Acetone precipitated 
protein  
3 4.900 0.033 150.769 
2.670 
 
 
